TNFRSF17 and Miyoshi myopathy: Modern management of relapsed MM is further complicated by the availability of diverse therapeutic options, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies, and novel therapies such as XPO1 inhibitor, bispecific antibodies and CAR-T cell therapy targeting BCMA and GPRC5d.